Science & Enterprise subscription

Follow us on Twitter

  • Make me wanna shout ... #BillsMafia https://t.co/iF1vhKHXtu
    about 2 hours ago
  • First of two podcasts with experiences of news photographers in the insurrection. Thanks @cherissmay for sharing yo… https://t.co/aCjPD6ct84
    about 18 hours ago
  • Half or more of American adults express negative opinions about the way Covid-19 vaccines are distributed, accordin… https://t.co/9l2SUpW85u
    about 24 hours ago
  • New post on Science and Enterprise: Infographic – US Public Down on Vaccine Rollout https://t.co/vegz3ihvIO #Science #Business
    about 24 hours ago
  • We've written several times about Lander and his work, including companies he founded. ... Biden to Elevate Science… https://t.co/rWVGTa1gPL
    about 1 day ago

Please share Science & Enterprise

Neuroscience Biotech Acquired in $770M Deal

Brain activity graphic

A three year-old biotechnology company developing treatments for psychiatric and movement disorders is being acquired by global drug maker Novartis. . . . → Read More: Neuroscience Biotech Acquired in $770M Deal

Oral Drug Delivery Company Acquired in $1.8B Deal

Investor screen

Emisphere Technologies, developers of a process that makes biologic drugs available as oral medicines is being acquired by drug maker Novo Nordisk. . . . → Read More: Oral Drug Delivery Company Acquired in $1.8B Deal

Venture Rounds, IPOs, Mergers Vanish in Election Week

White House

Nationwide jitters in the U.S. appear to be affecting venture capital activities in the week of the presidential and congressional elections. . . . → Read More: Venture Rounds, IPOs, Mergers Vanish in Election Week

Bayer Gains Gene Therapy Biotech in $4B Deal

AskBio Bioreactor

Global drug maker Bayer AG is acquiring the company Asklepios BioPharmaceutical, developer of gene therapies to treat inherited disorders. . . . → Read More: Bayer Gains Gene Therapy Biotech in $4B Deal

Lilly Gains Neuro Disease Biotech in $1.36B Deal

Nerve cells illustration

Drug maker Eli Lilly and Co. is acquiring Disarm Therapeutics, a biotechnology company developing treatments for neurodegenerative disorders. . . . → Read More: Lilly Gains Neuro Disease Biotech in $1.36B Deal

Heart Disease Biotech Acquired in $13.1B Deal

Wall Street sign

A company developing precision medicine drugs to treat inherited heart disorders was acquired by drug maker Bristol Myers Squibb, or BMS, for $13.1 billion. . . . → Read More: Heart Disease Biotech Acquired in $13.1B Deal

Cancer Screening Analytics Company Acquired in $8B Deal

Blood sample vials

A company creating a blood test to screen for multiple types of cancer is being acquired by genomics analytics company Illumina for $8 billion in cash and stock. . . . → Read More: Cancer Screening Analytics Company Acquired in $8B Deal

Gilead Acquires Cancer Therapy Biotech for $21B

Investment graphic

Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion. . . . → Read More: Gilead Acquires Cancer Therapy Biotech for $21B

Food Allergy Biotech Acquired for $2.6B

Palforzia capsules

Aimmune Therapeutics Inc., a developer of food allergy drugs, was acquired today by global consumer products company Nestlé for $2.6 billion. . . . → Read More: Food Allergy Biotech Acquired for $2.6B

Sanofi Acquires Immune Disease Biotech in $3.7B Deal

Human B-cell

A developer of small-molecule therapies for autoimmune diseases, including multiple sclerosis, and other immune disorders is being acquired by Sanofi. . . . → Read More: Sanofi Acquires Immune Disease Biotech in $3.7B Deal